Marshall Wace LLP Sells 301,046 Shares of Genmab A/S (NASDAQ:GMAB)

Marshall Wace LLP decreased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 31.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 648,379 shares of the company’s stock after selling 301,046 shares during the period. Marshall Wace LLP’s holdings in Genmab A/S were worth $16,294,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. raised its stake in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the last quarter. Renaissance Technologies LLC increased its position in Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares during the last quarter. Headlands Technologies LLC lifted its holdings in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the period. Finally, Choreo LLC purchased a new position in Genmab A/S in the second quarter worth about $776,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

GMAB has been the subject of several research reports. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. BTIG Research raised their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial lowered their price target on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Friday, September 20th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Hold” and a consensus target price of $45.20.

Genmab A/S Stock Performance

GMAB stock opened at $24.33 on Friday. The company’s fifty day moving average price is $26.97 and its 200-day moving average price is $27.79. Genmab A/S has a one year low of $23.80 and a one year high of $35.88. The company has a market capitalization of $16.10 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 0.73 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. On average, research analysts predict that Genmab A/S will post 1.27 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.